Wall Street brokerages forecast that Zoetis Inc (NYSE:ZTS) will post earnings per share (EPS) of $0.82 for the current quarter, Zacks reports. Four analysts have provided estimates for Zoetis’ earnings, with estimates ranging from $0.80 to $0.85. Zoetis reported earnings per share of $0.77 during the same quarter last year, which would indicate a positive year over year growth rate of 6.5%. The firm is scheduled to report its next quarterly earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Zoetis will report full year earnings of $3.48 per share for the current financial year, with EPS estimates ranging from $3.43 to $3.50. For the next financial year, analysts forecast that the company will report earnings of $3.89 per share, with EPS estimates ranging from $3.81 to $3.93. Zacks’ EPS averages are an average based on a survey of research analysts that cover Zoetis.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, beating the consensus estimate of $0.79 by $0.09. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same period in the prior year, the business earned $0.75 earnings per share. The business’s quarterly revenue was up 6.5% on a year-over-year basis.
Several analysts recently commented on the stock. Gabelli downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target for the company. in a research report on Thursday, May 2nd. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $113.00 price target for the company in a research report on Friday, April 19th. BMO Capital Markets upped their price target on shares of Zoetis from $101.00 to $105.00 and gave the company a “market perform” rating in a research report on Thursday, May 9th. UBS Group assumed coverage on shares of Zoetis in a research report on Wednesday, March 20th. They issued a “neutral” rating for the company. Finally, SunTrust Banks began coverage on shares of Zoetis in a research report on Tuesday, March 19th. They issued a “hold” rating and a $100.00 price target for the company. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and an average price target of $103.15.
ZTS stock opened at $101.25 on Monday. Zoetis has a 12 month low of $78.90 and a 12 month high of $103.97. The company has a market cap of $48.51 billion, a P/E ratio of 32.35, a price-to-earnings-growth ratio of 2.53 and a beta of 0.91. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84.
In related news, insider Roman Trawicki sold 17,873 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $95.10, for a total value of $1,699,722.30. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Juan Ramon Alaix sold 312,109 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $94.06, for a total transaction of $29,356,972.54. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 433,661 shares of company stock worth $41,267,685. 0.29% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of ZTS. Fulcrum Equity Management acquired a new stake in Zoetis in the 4th quarter worth $841,000. RPg Family Wealth Advisory LLC lifted its holdings in shares of Zoetis by 24,302.0% during the 4th quarter. RPg Family Wealth Advisory LLC now owns 48,804 shares of the company’s stock worth $4,175,000 after acquiring an additional 48,604 shares during the period. IFM Investors Pty Ltd lifted its holdings in shares of Zoetis by 9.9% during the 4th quarter. IFM Investors Pty Ltd now owns 27,848 shares of the company’s stock worth $2,382,000 after acquiring an additional 2,516 shares during the period. OLD National Bancorp IN lifted its holdings in shares of Zoetis by 1.2% during the 4th quarter. OLD National Bancorp IN now owns 25,604 shares of the company’s stock worth $2,190,000 after acquiring an additional 299 shares during the period. Finally, WealthPLAN Partners LLC lifted its holdings in shares of Zoetis by 6.4% during the 4th quarter. WealthPLAN Partners LLC now owns 3,894 shares of the company’s stock worth $371,000 after acquiring an additional 233 shares during the period. Institutional investors and hedge funds own 90.78% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Analyzing a company’s cash flow statement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.